Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone011-49-2148-7600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.93 million
Profitability
Miscellaneous
Employees149
Next Earnings Date11/15/2019 (Estimated)
OptionableNot Optionable
BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions
What is BIOFRONTERA AG/ADR's stock symbol?
BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA."
How were BIOFRONTERA AG/ADR's earnings last quarter?
BIOFRONTERA AG/ADR (NASDAQ:BFRA) issued its quarterly earnings results on Tuesday, August, 27th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.82. The business had revenue of $7.98 million for the quarter. BIOFRONTERA AG/ADR had a net margin of 4.48% and a return on equity of 6.82%. View BIOFRONTERA AG/ADR's Earnings History.
When is BIOFRONTERA AG/ADR's next earnings date?
What guidance has BIOFRONTERA AG/ADR issued on next quarter's earnings?
BIOFRONTERA AG/ADR updated its third quarter 2019 earnings guidance on Thursday, October, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.51455-5.845423 million, compared to the consensus revenue estimate of $7.8 million.
What price target have analysts set for BFRA?
2 Wall Street analysts have issued 12 month target prices for BIOFRONTERA AG/ADR's stock. Their predictions range from $11.00 to $11.00. On average, they anticipate BIOFRONTERA AG/ADR's stock price to reach $11.00 in the next year. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for BIOFRONTERA AG/ADR.
What is the consensus analysts' recommendation for BIOFRONTERA AG/ADR?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOFRONTERA AG/ADR.
Has BIOFRONTERA AG/ADR been receiving favorable news coverage?
Media coverage about BFRA stock has been trending positive on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIOFRONTERA AG/ADR earned a news impact score of 2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for BIOFRONTERA AG/ADR.
Who are some of BIOFRONTERA AG/ADR's key competitors?
Some companies that are related to BIOFRONTERA AG/ADR include ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH), Gossamer Bio (GOSS), AnaptysBio (ANAB), TherapeuticsMD (TXMD), Endo International (ENDP), Epizyme (EPZM), Amneal Pharmaceuticals (AMRX), Odonate Therapeutics (ODT), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), ANI Pharmaceuticals (ANIP) and Phibro Animal Health (PAHC).
What other stocks do shareholders of BIOFRONTERA AG/ADR own?
Who are BIOFRONTERA AG/ADR's key executives?
BIOFRONTERA AG/ADR's management team includes the folowing people:
- Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 63)
- Mr. Thomas Schaffer, CFO & Member of Management Board (Age 56)
- Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 51)
- Mr. Alexander Richardson, Head of UK Sales Team
When did BIOFRONTERA AG/ADR IPO?
(BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.
How do I buy shares of BIOFRONTERA AG/ADR?
Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BIOFRONTERA AG/ADR's stock price today?
One share of BFRA stock can currently be purchased for approximately $11.86.
How big of a company is BIOFRONTERA AG/ADR?
What is BIOFRONTERA AG/ADR's official website?
How can I contact BIOFRONTERA AG/ADR?
BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]
MarketBeat Community Rating for BIOFRONTERA AG/ADR (NASDAQ BFRA)
MarketBeat's community ratings are surveys of what our community members think about BIOFRONTERA AG/ADR and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
